Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2025)

Apimeds Pharmaceuticals US has reported Common Equity for 3 years, with the latest figure at $153.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 11391.18% year-over-year to $153.3 million; the trailing twelve-month figure through Dec 2025 stood at $153.3 million (up 11391.18% YoY), and the FY2025 full-year result was $153.3 million, up 11391.18% from the prior year.
• Common Equity for Q4 2025 stood at $153.3 million, up from $8.2 million in the prior quarter.
• The five-year high for Common Equity was $153.3 million in Q4 2025, with the low at -$1.8 million in Q1 2025.
• Historically, Common Equity has averaged $18.5 million across 3 years, with a median of -$264604.0 in 2024.
• Annual changes were most pronounced in 2024 — Common Equity plunged 4361.57% — and 2025, when it jumped 11391.18%.
• Apimeds Pharmaceuticals US's Common Equity stood at $31869.0 in 2023, then sank by 4361.57% to -$1.4 million in 2024, then jumped by 11391.18% to $153.3 million in 2025.
• The last three Common Equity figures came in at $153.3 million (Q4 2025), $8.2 million (Q3 2025), and $9.7 million (Q2 2025), per Business Quant data.